share_log

NLS Pharmaceutics Receives Notice Of Allowance For U.S. Patent Titled 'MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER'

NLS Pharmaceutics Receives Notice Of Allowance For U.S. Patent Titled 'MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER'

NLS Pharmacetics收到名为 “海洛因依赖和药物滥用障碍的MAZINDOL疗法” 的美国专利的批准通知
Benzinga Real-time News ·  2022/12/01 01:01

$NLS Pharmaceutics (NLSP.US)$ Receives Notice Of Allowance For U.S. Patent Titled 'MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER'

$NLS Pharmaceutics (NLSP.US)$收到名为 “MAZINDOL治疗海洛因依赖和药物滥用障碍” 的美国专利的批准通知

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发